Skip to content
Screener

Icahn Enterprises IEP Pharma — Revenue

Other segment segments

Energy
$2.75B+55.2%
Automotive
$354M-2.2%
Investment
-$303M-1,415%
Food Packaging
$90M-7.2%
Home Fashion
$38M-9.5%
Real Estate
$27M-59.7%
Holding Company
$7M-61.1%

Similar metrics at other companies

Paysign logo
PAYSPharma Industry — Revenue
$14.65M+88.9%
GoodRx Holdings, Inc. logo
GDRXPharma Direct revenue — Revenue
$61.63M+76.2%
Paysign logo
PAYSPlasma Industry — Revenue
$13.04M+21.4%
CVS Health logo
CVSPharmacy & Consumer Wellness — Revenue
$33.82B+0.7%
Grid Dynamics Holdings, Inc. logo
GDYNHealthcare and Pharma — Revenue
$2.15M-10.4%
Weis Markets logo
WMKPharmacy — Revenue
$167.19M+5.4%

Other financials

Income statement

See full
Revenue$3.0B+25.6%
Net income-$355.0M-115%
EPS (diluted)-$0.52-73.3%

Balance sheet

See full
Cash & equivalents$1.2B-32.3%
Total debt$6.9B-5.2%
Total assets$12.9B-13.1%

Cash flow

See full
Operating cash flow$116.0M-57.8%
CapEx$80.0M-16.7%
Free cash flow$36.0M

Valuation

See full
Market cap$5.01B+2.3%
Enterprise value$10.72B+3.0%
P/S0.5×0.0×

Profitability

See full
Gross margin-56.5%
Net margin-5%-1.1pp
FCF margin-2.3%

Returns & leverage

See full
Return on equity-0.1%
Debt / equity0.7×

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-090605
Line itemInvestmentEnergyAutomotiveFood PackagingReal EstateHome FashionPharmaHolding CompanyConsolidated
Interest and dividend income3165749
(Loss) gain on disposition of assets, net(2)1(1)
Other income (loss), net33(1)5
(303)2,7453549027381772,975
Expenses:
Cost of goods sold2,632135782992,883
Other expenses from operations12423147
Dividend expense55

Item 1. Financial Statements (Unaudited)

FAQ

What is Icahn Enterprises's pharma — revenue?
Icahn Enterprises (IEP) reported pharma — revenue of $17M in Q2 2026.
How has Icahn Enterprises's pharma — revenue changed year-over-year?
Icahn Enterprises's pharma — revenue decreased by 50.0% year-over-year, from $34M to $17M.
What is the long-term trend for Icahn Enterprises's pharma — revenue?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — revenue has grown at a 5.4% compound annual growth rate (CAGR), from $85M to $105M.
What does pharma — revenue mean?
The aggregate top-line income for the pharmaceutical segment, combining net product sales and other operating revenues. This figure represents the total inflow of economic benefits from all segment-related business activities.

Ask your AI about Icahn Enterprises's pharma — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude